PL172830B1 - Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL - Google Patents

Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL

Info

Publication number
PL172830B1
PL172830B1 PL93317972A PL31797293A PL172830B1 PL 172830 B1 PL172830 B1 PL 172830B1 PL 93317972 A PL93317972 A PL 93317972A PL 31797293 A PL31797293 A PL 31797293A PL 172830 B1 PL172830 B1 PL 172830B1
Authority
PL
Poland
Prior art keywords
hydrochloride
crystalline
active ingredient
bacteria
crystalline hydrate
Prior art date
Application number
PL93317972A
Other languages
English (en)
Polish (pl)
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PL172830B1 publication Critical patent/PL172830B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL93317972A 1992-07-31 1993-07-29 Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL PL172830B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
PL172830B1 true PL172830B1 (pl) 1997-12-31

Family

ID=16499234

Family Applications (2)

Application Number Title Priority Date Filing Date
PL93317972A PL172830B1 (pl) 1992-07-31 1993-07-29 Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL
PL93299870A PL172835B1 (pl) 1992-07-31 1993-07-29 Chlorowodorek kwasu 7- ß -[(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3 -cefemo-4-karboksylowego oraz sposób jego wytwarzania, krystaliczny wodzian chlorowodorku kwasu 7- ß -(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3-ce- femo-4-karboksylowego oraz sposób jego wytwarzania PL PL PL PL PL

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL93299870A PL172835B1 (pl) 1992-07-31 1993-07-29 Chlorowodorek kwasu 7- ß -[(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3 -cefemo-4-karboksylowego oraz sposób jego wytwarzania, krystaliczny wodzian chlorowodorku kwasu 7- ß -(Z)-2-(2-amino-4-tiazolilo)-2-hydroksyiminoacetamido]-3-(1,2,3-triazol-4-ilo)-tiometylotio-3-ce- femo-4-karboksylowego oraz sposób jego wytwarzania PL PL PL PL PL

Country Status (23)

Country Link
US (1) US5407929A (enExample)
EP (1) EP0581552B1 (enExample)
KR (1) KR100245938B1 (enExample)
CN (1) CN1037683C (enExample)
AT (1) ATE165360T1 (enExample)
AU (1) AU657866B2 (enExample)
BR (1) BR9303235A (enExample)
CA (1) CA2101502A1 (enExample)
DE (1) DE69318077T2 (enExample)
ES (1) ES2115725T3 (enExample)
FI (1) FI933391L (enExample)
GR (1) GR3026699T3 (enExample)
HU (1) HU219637B (enExample)
IL (1) IL106516A (enExample)
MX (1) MX9304611A (enExample)
NO (1) NO303734B1 (enExample)
NZ (1) NZ248285A (enExample)
PH (1) PH30109A (enExample)
PL (2) PL172830B1 (enExample)
RU (1) RU2118959C1 (enExample)
TW (1) TW307769B (enExample)
UA (1) UA37181C2 (enExample)
ZA (1) ZA935529B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1757606T3 (da) * 2001-02-24 2009-09-07 Boehringer Ingelheim Pharma Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CA2513837A1 (en) 2003-02-12 2004-08-26 Paul Adriaan Van Der Schaaf Crystalline forms of pitavastatin calcium
CN1751051B (zh) 2003-03-27 2010-06-09 巴斯利尔药物股份公司 结晶形式的头孢菌素
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP5323684B2 (ja) * 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
KR940005636A (ko) 1994-03-22
DE69318077D1 (de) 1998-05-28
FI933391A7 (fi) 1994-02-01
AU657866B2 (en) 1995-03-23
CN1037683C (zh) 1998-03-11
PH30109A (en) 1996-12-27
IL106516A0 (en) 1993-11-15
HU9302194D0 (en) 1993-10-28
NO303734B1 (no) 1998-08-24
ZA935529B (en) 1994-02-24
HU219637B (hu) 2001-06-28
ATE165360T1 (de) 1998-05-15
NZ248285A (en) 1994-07-26
KR100245938B1 (ko) 2000-04-01
AU4422793A (en) 1994-02-03
CN1089948A (zh) 1994-07-27
EP0581552B1 (en) 1998-04-22
HUT68602A (en) 1995-06-28
TW307769B (enExample) 1997-06-11
NO932745L (no) 1994-02-01
RU2118959C1 (ru) 1998-09-20
FI933391A0 (fi) 1993-07-29
IL106516A (en) 1998-06-15
BR9303235A (pt) 1994-03-01
PL299870A1 (en) 1994-02-07
EP0581552A2 (en) 1994-02-02
GR3026699T3 (en) 1998-07-31
PL172835B1 (pl) 1997-12-31
ES2115725T3 (es) 1998-07-01
FI933391L (fi) 1994-02-01
NO932745D0 (no) 1993-07-30
DE69318077T2 (de) 1998-10-29
EP0581552A3 (en) 1994-06-01
US5407929A (en) 1995-04-18
CA2101502A1 (en) 1994-02-01
UA37181C2 (uk) 2001-05-15
MX9304611A (es) 1994-02-28

Similar Documents

Publication Publication Date Title
PL172830B1 (pl) Preparat farmaceutyczny do zwalczania bakterii PL PL PL PL PL
CA2155322C (en) Crystalline ceftiofur free acid
KR0180798B1 (ko) 결정성 페니실린 유도체, 그의 제법 및 용도
HU200777B (en) Process for producing crystalline cefalosporinhydrate and capsules comprising same
CS214721B2 (en) Method of making the pentahydrate of +l6r,7r+p-7-+l+lz+p-2-+l2-aminothiazol-4-yl+p-2-+l2-carboxyprop-2-oxyimino+p acetamido+p-3-+l1-piridiniummethyl+pcef-3-em-4-carboxylate
JP2002505328A (ja) 抗潰瘍医薬の硝酸塩
SE449996B (sv) (6r,7r)-7-/(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxiprop-2-oxiimino)acetamidol/-3-(1-pyridiniummetyl)cef-3-em-4-karboxylat i form av en kristallin bishydroklorid farmaceutisk komposition derav samt anvendning som mellanpr
US4189479A (en) Cephalosporin esters
JPH03500536A (ja) セファロスポリン抗生物質類
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
AU631960B2 (en) Crystalline hydrochloride of new beta-lactam antibiotic and process therefor
CA2519272C (en) Cephalosporin in crystalline form
US8470809B2 (en) Crystalline sodium salt of cephalosporin antibiotic
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
EP2324034A2 (en) Crystalline sodium salt of cephalosporin antibiotic
JPH01301683A (ja) 新規セフエム化合物
HU210527A9 (hu) Cefalosporin kristályos hidrátja orális alkalmazáshoz és az ezt tartalmazó készítmény Az átmeneti oltalom az 1-4. és 15-17. igénypontokra vonatkozik.
LU83588A1 (de) Cephalosporinderivate
HK1085479B (en) Cephalosporin in crystalline form
SI8012497A8 (sl) Postopek za pridobivanje (6r,7r)-7-/(z)-2- (2-aminotiazol)-4-il-)-2-(karboksiprop-2-okiimino) acetamido/-3- (1-piridinium-metil)-cef-3-em-4-karboksilat pentahidratov